Soluble CD33 Antagonist Sequesters S100A9 to Block MDSC Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Myelodysplastic syndromes (MDS) patients experience impaired hematopoiesis due to the accumulation of CD33+ myeloid-derived suppressor cells (MDSCs) in the bone marrow, which is mediated by S100A9 as an endogenous ligand for CD33 initiated signaling, leading to ineffective erythropoiesis and resistance to current treatments.
Innovation Solution
Administering a CD33/S100A9 antagonist that binds and sequesters S100A9, inhibiting its activation of MDSCs, using recombinant fusion proteins comprising the ectodomain of CD33, Toll-like Receptor 4 (TLR4), or Receptor for Advanced Glycation End Products (RAGE) linked to an immunoglobulin Fc region, to block the S100A9 binding to CD33 receptors on MDSCs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lenalidomide is administered to treat MDS, then red blood cell transfusion independence is achieved in del5q patients, but response is limited in non-del5q patients and resistance emerges over time
Solution Approach 1:
The patent uses soluble CD33 (sCD33) as an intermediary molecule to block the interaction between S100A9 and CD33 receptors on MDSCs. This intermediary approach prevents the harmful signaling pathway that activates suppressor cells, thereby improving therapeutic response across different MDS subtypes including non-del5q cases where lenalidomide is ineffective.
Solution Approach 2:
The patent converts the harmful effect of CD33 signaling (which activates suppressor cells and impairs hematopoiesis) into a beneficial therapeutic target. By administering sCD33 to block this pathway, the patent transforms the disease mechanism into a treatable target, achieving durable responses and reducing transfusion dependence.
2Quantity of substance
If CD33+ MDSCs accumulate in bone marrow, then S100A9 initiates signaling through CD33, but this leads to impaired hematopoiesis and ineffective erythropoiesis
Solution Approach 1:
The patent extracts or removes the harmful signaling function by using sCD33 to sequester S100A9, preventing it from binding to CD33 receptors on MDSCs. This extraction of the pathological interaction restores normal hematopoietic function despite the presence of accumulated MDSCs in the bone marrow.
3Manufacturing precision
If current targeted therapies are used, then some cytogenetic abnormalities are corrected, but transfusion dependence resumes after median of 2.5 years
Solution Approach 1:
The patent establishes continuous therapeutic action by blocking the S100A9-CD33 pathway, which drives MDSC activation and suppressor cell function. This continuous blockade prevents the emergence of resistance and maintains durable responses, extending the duration of therapeutic benefit beyond the median 2.5 years observed with current therapies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Inhibits the activation of MDSCs, thereby improving hematopoiesis and potentially providing a durable therapeutic response in MDS patients by reducing transfusion dependence and cytogenetic abnormalities.
Implementation Method 1
the CD33/S100A9 antagonist binds and sequesters endogenous S100A9 and inhibits its binding to CD33 receptor on MDSCs
Data Source
AI summary
Disclosed are compositions and methods for treating disease or condition caused or exacerbated by S100A9 activity, such as myelodysplastic syndromes (MDS) using a composition comprising an effective amount of a CD33/S100A9 inhibitor.